These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 16540766

  • 1. Weight loss as a treatment for nonalcoholic fatty liver disease.
    Clark JM.
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S39-43. PubMed ID: 16540766
    [Abstract] [Full Text] [Related]

  • 2. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
    Tilg H, Moschen A.
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):159-67. PubMed ID: 20485253
    [Abstract] [Full Text] [Related]

  • 3. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA.
    Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
    [Abstract] [Full Text] [Related]

  • 4. Effect of weight loss on nonalcoholic fatty liver disease.
    Patel AA, Torres DM, Harrison SA.
    J Clin Gastroenterol; 2009 Jan; 43(10):970-4. PubMed ID: 19727004
    [Abstract] [Full Text] [Related]

  • 5. Effects of weight loss on nonalcoholic fatty liver disease.
    Rafiq N, Younossi ZM.
    Semin Liver Dis; 2008 Nov; 28(4):427-33. PubMed ID: 18956298
    [Abstract] [Full Text] [Related]

  • 6. Combining behavioral and pharmacological treatments for obesity.
    Phelan S, Wadden TA.
    Obes Res; 2002 Jun; 10(6):560-74. PubMed ID: 12055334
    [Abstract] [Full Text] [Related]

  • 7. Therapy of nonalcoholic fatty liver disease: current status.
    Duvnjak M, Tomasic V, Gomercic M, Smircic Duvnjak L, Barsic N, Lerotic I.
    J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():57-66. PubMed ID: 20388946
    [Abstract] [Full Text] [Related]

  • 8. Nonalcoholic fatty liver disease and low-carbohydrate diets.
    York LW, Puthalapattu S, Wu GY.
    Annu Rev Nutr; 2009 Dec; 29():365-79. PubMed ID: 19575599
    [Abstract] [Full Text] [Related]

  • 9. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

  • 10. Nonalcoholic fatty liver disease.
    Angulo P.
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():52-6. PubMed ID: 17471859
    [Abstract] [Full Text] [Related]

  • 11. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R.
    Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
    [Abstract] [Full Text] [Related]

  • 12. Pharmacologic agents for the treatment of obesity.
    Mathys M.
    Clin Geriatr Med; 2005 Nov; 21(4):735-46, vii. PubMed ID: 16182086
    [Abstract] [Full Text] [Related]

  • 13. The impact of bariatric surgery on nonalcoholic fatty liver disease.
    de Freitas AC, Campos AC, Coelho JC.
    Curr Opin Clin Nutr Metab Care; 2008 May; 11(3):267-74. PubMed ID: 18403923
    [Abstract] [Full Text] [Related]

  • 14. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease.
    Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C, Königsrainer A, Königsrainer I, Kröber S, Niess A, Fritsche A, Häring HU, Stefan N.
    Gut; 2009 Sep; 58(9):1281-8. PubMed ID: 19074179
    [Abstract] [Full Text] [Related]

  • 15. Orlistat and sibutramine beyond weight loss.
    Mannucci E, Dicembrini I, Rotella F, Rotella CM.
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [Abstract] [Full Text] [Related]

  • 16. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH, Fernstrom JD.
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [Abstract] [Full Text] [Related]

  • 17. Long-term pharmacotherapy for obesity.
    Klein S.
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [Abstract] [Full Text] [Related]

  • 18. Non-alcoholic fatty liver disease from pathogenesis to management: an update.
    Musso G, Gambino R, Cassader M.
    Obes Rev; 2010 Jun; 11(6):430-45. PubMed ID: 19845871
    [Abstract] [Full Text] [Related]

  • 19. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach.
    Bellentani S, Dalle Grave R, Suppini A, Marchesini G, Fatty Liver Italian Network.
    Hepatology; 2008 Feb; 47(2):746-54. PubMed ID: 18098321
    [Abstract] [Full Text] [Related]

  • 20. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM.
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.